Table of Contents
I. CSHL Neuroscience of Addiction
II. Request for Applications (RFA): Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities (R01, Clinical Trial Optional RFA-OD-23-015
III. NIDA Genetics, Epigenetics, Cross-Cutting Research Team Meeting, Tuesday May 16 through Wednesday May 17, 2023, Natcher Auditorium, NIH Campus, Bethesda, MD. https://apps1.seiservices.com/NIDA/GeneticsConsortium/Default.aspx
----------------
I. CSHL Neuroscience of Addiction https://meetings.cshl.edu/courses.aspx?course=C-DRUG&year=23
August 9 - 15, 2023
Key Dates
Application Deadline: April 24, 2023
Arrival: August 8th by 6pm EST
Departure: August 15th around 12pm EST
The primary objective of the proposed workshop is to provide an intense dialogue of the fundamentals, state-of-the-art advances and major gaps in the cell and molecular biology of drug addiction. Targeted to new or experienced investigators, the workshop will combine formal presentations and informal discussions to convey the merits and excitement of cellular and molecular approaches to drug addiction research. With the advent of genomics and proteomics, an extraordinary opportunity now exists to develop comprehensive models of neuroadaptative processes fundamental to addiction, withdrawal, craving, relapse to drug use and general brain function.
A range of disciplines and topics will be represented, including:
- Noninvasive brain imaging to identify drug targets and adaptive processes
- Neuroadaptative processes at the molecular and cellular level
- Neural networks and their modulation
- Relevance of genotype to susceptibility and drug response
- Tolerance and adaptation at the cellular level
- Approaches to exploiting the daunting volume generated by neuroinformatics
Application Deadline: April 24, 2023 click here to apply
------------
II. Request for Applications (RFA): Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities (R01, Clinical Trial Optional) RFA-OD-23-015
The NIH Office of Disease Prevention (ODP), NIDA, and participating Institutes, Centers, and Offices are soliciting revision applications to active NIH grants through RFA-OD-23-015, Request for Applications (RFA): Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities (R01, Clinical Trial Optional).
We encourage all eligible grantees to apply.
This RFA is designed to help active NIH R01 grantees enhance their current smoking cessation and/or other prevention intervention studies by adding components focused on menthol cigarette smoking in populations that experience health disparities (racial and ethnic minority populations [American Indian or Alaska Native, Asian American, Black or African American, Native Hawaiian or Pacific Islander, Latino or Hispanic], less privileged socioeconomic status populations, underserved rural populations, and sexual and gender minorities).
Parent awards that involve prospective testing of an intervention or intervention implementation strategy, intervention development, or pilot/feasibility testing are the most appropriate for this funding opportunity.
A one-time supplement of up to $150,000 direct costs may be requested. The application due date is June 19, 2023, by 5:00 p.m. local time of the applicant organization.
Refer to the full RFA in the NIH Guide (RFA-OD-23-015) for complete eligibility, application, and submission information. Please direct all inquiries to the scientific/research contacts listed in the funding opportunity
.
III. NIDA Genetics, Epigenetics, Cross-Cutting Research Team Meeting, Tuesday May 16 through Wednesday May 17, 2023, Natcher Auditorium, NIH Campus, Bethesda, MD. https://apps1.seiservices.com/NIDA/GeneticsConsortium/Default.aspx
The Genetics and Epigenetics Cross-Cutting Research Team of the National Institute on Drug Abuse invites you to register for the May 16-17, 2023 NIDA Genetics and Epigenetics Cross- Cutting Research Team Meeting at Natcher Conference Center, Bldg 45 on the NIH Campus in Bethesda, MD. This is an in-person meeting.
There is no registration fee to attend this meeting. However, attendees are responsible for their own travel, meals, and lodging.
The goals of the meeting are to:
• Showcase the exciting research on the genetics and epigenetics of substance use disorders.
• Encourage collaboration among investigators with different expertise in genetics and epigenetics.
• Foster collaboration between investigators working on the genetics and epigenetics of substance abuse disorders and HIV/AIDS investigators.
• Identify new research opportunities in the genetics and epigenetics of substance use disorders.
• Provide attendees with an opportunity to meet with NIDA program directors to discuss their ideas for grant applications and funding opportunities
To register: https://apps1.seiservices.com/NIDA/GeneticsConsortium/Default.aspx
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L
